Valsts: Amerikas Savienotās Valstis
Valoda: angļu
Klimata pārmaiņas: NLM (National Library of Medicine)
RISEDRONATE SODIUM (UNII: OFG5EXG60L) (RISEDRONIC ACID - UNII:KM2Z91756Z)
Macleods Pharmaceuticals Limited
RISEDRONATE SODIUM
RISEDRONATE SODIUM 5 mg
ORAL
PRESCRIPTION DRUG
Risedronate sodium tablets, USP are indicated for the treatment and prevention of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, risedronate sodium tablets, USP reduces the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see Clinical Studies (14.1, 14.2) ]. Risedronate sodium tablets, USP are indicated for treatment to increase bone mass in men with osteoporosis. Risedronate sodium tablets, USP are indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of greater than or equal to 7.5 mg of prednisone or equivalent) for chronic diseases. Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Risedronate sodium tablets, USP are indicated for treatment of Paget's disease of bone in men and women. The optimal duration of use has not been determined. T
Risedronate sodium tablets, USP are available as follows: 5 mg yellow coloured, circular, biconvex, film-coated tablet debossed with "CL 90" on one side and plain on other side. NDC 33342-107-07 bottle of 30 NDC 33342-107-49 bottle of 2000 NDC 33342-107-06 Unit dose tablets pack of 30 (3 x 10) 30 mg white to off white, circular, biconvex, film-coated tablet debossed with "CL 91" on one side and plain on other side. NDC 33342-108-07 bottle of 30 NDC 33342-108-15 bottle of 500 NDC 33342-108-06 Unit dose tablets pack of 30 (3 x 10) 35 mg orange coloured, circular, biconvex, film-coated tablet debossed with "CL 92" on one side and plain on the other side. NDC 33342-109-37 dose pack of 4 NDC 33342-109-50 dose pack of 12 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15°C to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
Abbreviated New Drug Application
Macleods Pharmaceuticals Limited ---------- SPL MEDGUIDE SECTION Risedronate Sodium tablets, USP (RIS-e-DROE-nate SOE-dee-um) Read the Medication Guide that comes with risedronate sodium tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment. Talk to your doctor if you have any questions about risedronate sodium tablets, there may be new information about it. What is the most important information I should know about risedronate sodium tablets? Risedronate sodium tablets can cause serious side effects including: 1. Esophagus problems 2. Low calcium levels in your blood (hypocalcemia) 3. Severe jaw bone problems (osteonecrosis) 4. Bone, joint, or muscle pain 5. Unusual thigh bone fractures 1. Esophagus problems. Some people who take risedronate sodium tablets may develop problems in the esophagus (the tube that connects the mouth and the stomach). These problems include irritation, inflammation, or ulcers of the esophagus which may sometimes bleed. • It is important that you take risedronate sodium tablets exactly as prescribed to help lower your chance of getting esophagus problems. (See the section “How should I take risedronate sodium tablets?”) • Stop taking risedronate sodium tablets and call your doctor right away if you get chest pain, new or worsening heartburn, or have trouble or pain when you swallow. 2. Low calcium levels in your blood (hypocalcemia). Risedronate sodium tablets may lower the calcium levels in your blood. If you have low blood calcium before you start taking Risedronate sodium tablets, it may get worse during treatment. Your low blood calcium must be treated before you take risedronate sodium tablets. Most people with low blood calcium levels do not have symptoms, but some people may have symptoms. Call your doctor right away if you have symptoms of low blood calcium such as: • Spasms, twitches, or cramps in your musc Izlasiet visu dokumentu
RISEDRONATE SODIUM - RISEDRONATE SODIUM TABLET, FILM COATED MACLEODS PHARMACEUTICALS LIMITED ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE RISEDRONATE SODIUM TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR RISEDRONATE SODIUM TABLETS. RISEDRONATE SODIUM TABLETS, USP, FOR ORAL USE INITIAL U.S. APPROVAL: 1998 INDICATIONS AND USAGE Risedronate sodium tablet, USP is a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis (1.1) Treatment to increase bone mass in men with osteoporosis (1.2) Treatment and prevention of glucocorticoid-induced osteoporosis (1.3) Treatment of Paget's disease (1.4) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. (1.5) DOSAGE AND ADMINISTRATION Treatment of Postmenopausal Osteoporosis: 5 mg daily, 35 mg once-a-week, 75 mg two consecutive days each month (2.1) Prevention of Postmenopausal Osteoporosis: 5 mg daily, 35 mg once-a-week(2.2) Men with Osteoporosis: 35 mg once-a-week (2.3) Glucocorticoid-Induced Osteoporosis: 5 mg daily (2.4) Paget's Disease: 30 mg daily for 2 months (2.5) Instruct patients to: • Swallow tablet whole with 6 to 8 ounces of plain water, at least 30 minutes before the first food, beverage, or medication of the day • Avoid lying down for 30 minutes (2) • Take supplemental calcium and vitamin D if dietary intake is inadequate (2.7) DOSAGE FORMS AND STRENGTHS Tablets: 5, 30, 35 mg (3) CONTRAINDICATIONS • Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia (4, 5.1) • Inability to stand or sit upright for at least 30 minutes (4, 5.1) • Hypocalcemia (4, 5.2) • Known hypersensitivity to any component of this product (4, 6.2) WARNINGS AND PRECAUTIONS • _Products Containing Same Active Ingredient:_ Patients receiving Atelvia should not be treated with risedronate sodium tablets (5.1) • Izlasiet visu dokumentu